PIK3CA and chordoma: To assess whether the treatments affect the activity of PI3K signaling, Western blot analyses were performed: chordoma cell lines were treated for six hours with buparlisib monotherapy or a combination of palbociclib (0.5 μM) and rapamycin (1 μM).